Lori S. Friedman
ORIC Pharmaceuticals, Inc. (United States) · 468 works · 16,104 citations · h-index 58
Top works
- Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- Closing in on a breast cancer gene on chromosome 17q.
- THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21.
- Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q
- Involvement of Brca2 in DNA Repair
- Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.
- Mutation analysis of the BRCA1 gene in ovarian cancers.
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome
- The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
- Mitotic Checkpoint Inactivation Fosters Transformation in Cells Lacking the Breast Cancer Susceptibility Gene, Brca2
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
- High-Density Genetic Map of the BRCA1 Region of Chromosome 17q12-q21
- Drosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
- Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer